Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes News and Research
Diabetes News
Leaders team for Insulin and T2 drugs etc
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="Cowboyjim" data-source="post: 157643" data-attributes="member: 23128"><p>Biocon and Pfizer have teamed for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. </p><p><a href="http://www.prnewswire.com/news-releases/biocon-and-pfizer-enter-into-global-commercialization-agreement-105162969.html" target="_blank">http://www.prnewswire.com/news-releases/biocon-and-pfizer-enter-into-global-commercialization-agreement-105162969.html</a></p><p></p><p>The Max Planck Institute (MPI) of Biochemistry in Martinsried and GlaxoSmithKline GmbH & Co. KG (GSK) will jointly develop new drugs for the treatment of Type II diabetes. A scientist Axel Ullrich, Director at the MPI of Biochemistry, has had earlier success: he and fellow scientist Mathias Bäcker described the role of certain protein molecules - known as kinases - in connection with the development of T2 so likely GSK wants to bring innovative drugs using this approach to market.</p><p><a href="http://www.medicalnewstoday.com/articles/204962.php" target="_blank">http://www.medicalnewstoday.com/articles/204962.php</a></p><p></p><p>In another news item someone is dealing with how insulin sensitivity may explain link between obesity, memory problems...."The study shows that impaired insulin sensitivity, which generally accompanies obesity, may serve as a mediator between midlife obesity and cognitive decline later on". Cheery stuff... 8) </p><p><a href="http://www.eurekalert.org/pub_releases/2010-10/uota-ism101910.php" target="_blank">http://www.eurekalert.org/pub_releases/2010-10/uota-ism101910.php</a></p></blockquote><p></p>
[QUOTE="Cowboyjim, post: 157643, member: 23128"] Biocon and Pfizer have teamed for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. [url]http://www.prnewswire.com/news-releases/biocon-and-pfizer-enter-into-global-commercialization-agreement-105162969.html[/url] The Max Planck Institute (MPI) of Biochemistry in Martinsried and GlaxoSmithKline GmbH & Co. KG (GSK) will jointly develop new drugs for the treatment of Type II diabetes. A scientist Axel Ullrich, Director at the MPI of Biochemistry, has had earlier success: he and fellow scientist Mathias Bäcker described the role of certain protein molecules - known as kinases - in connection with the development of T2 so likely GSK wants to bring innovative drugs using this approach to market. [url]http://www.medicalnewstoday.com/articles/204962.php[/url] In another news item someone is dealing with how insulin sensitivity may explain link between obesity, memory problems...."The study shows that impaired insulin sensitivity, which generally accompanies obesity, may serve as a mediator between midlife obesity and cognitive decline later on". Cheery stuff... 8) [url]http://www.eurekalert.org/pub_releases/2010-10/uota-ism101910.php[/url] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
Leaders team for Insulin and T2 drugs etc
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…